miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell
July 21 2017 - 10:00AM
What: miRagen Therapeutics,
Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company
focused on the discovery and development of RNA-targeted therapies,
will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, William S. Marshall, Ph.D.,
President and Chief Executive Officer, will ring the
Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Monday, July 24, 2017 – 3:45 p.m. to 4:00
p.m. ET
miRagen Therapeutics, Inc. Media Contact:Adam
Levy(720) 407-4595alevy@miragenrx.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About miRagen Therapeutics, Inc.miRagen
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
discovering and developing proprietary RNA-targeted therapies with
a specific focus on microRNAs and their role in diseases where
there is a high unmet medical need. miRagen’s two lead product
candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical
trials. miRagen’s clinical product candidate for the treatment of
certain cancers, MRG-106, is an inhibitor of microRNA-155, which is
found at abnormally high levels in several blood cancers. miRagen’s
clinical product candidate for the treatment of pathological
fibrosis, MRG-201, is a replacement for microRNA-29, which is found
at abnormally low levels in a number of pathological fibrotic
conditions, including cutaneous, cardiac, renal, hepatic, and
pulmonary fibrosis, as well as systemic sclerosis. In addition to
miRagen’s clinical programs, it is developing a pipeline of
pre-clinical product candidates. The goal of miRagen’s
translational medicine strategy is to progress rapidly to first in
human studies once it has established the pharmacokinetics,
pharmacodynamics and safety of the product candidate in
pre-clinical studies. For more information, please
visit www.miragenrx.com.
For information on clinical trials please
visit www.clinicaltrials.gov.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to 3,800 total listings with a market
value of $11 trillion. To learn more, visit:
http://business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024